Next Article in Journal
Current Insights on Antifungal Therapy: Novel Nanotechnology Approaches for Drug Delivery Systems and New Drugs from Natural Sources
Previous Article in Journal
Evaluation of Tissue and Circulating miR-21 as Potential Biomarker of Response to Chemoradiotherapy in Rectal Cancer
Previous Article in Special Issue
Phenotypic Screening in C. elegans as a Tool for the Discovery of New Geroprotective Drugs
Review

Clinical Evidence for Targeting NAD Therapeutically

1
Health Longevity Performance Optimisation Institute, Cambridge CB22 5NE, UK
2
Fight Aging!, 4736 Onondaga Blvd, PMB 179, Syracuse, NY 13219, USA
3
Buck Institute for Research on Aging, Novato, CA 94945, USA
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2020, 13(9), 247; https://doi.org/10.3390/ph13090247
Received: 18 August 2020 / Revised: 8 September 2020 / Accepted: 10 September 2020 / Published: 15 September 2020
(This article belongs to the Special Issue Aging and Drug Discovery)
Nicotinamide adenine dinucleotide (NAD) pharmacology is a promising class of treatments for age-related conditions that are likely to have a favorable side effect profile for human use, given the widespread use of the NAD precursor vitamin B3 supplements. However, despite several decades of active investigation and numerous possible biochemical mechanisms of action suggested, only a small number of randomized and adequately powered clinical trials of NAD upregulation as a therapeutic strategy have taken place. We conducted a systematic review of the literature, following the PRISMA guidelines, in an attempt to determine whether or not the human clinical trials performed to date support the potential benefits of NAD supplementation in a range of skin, metabolic and age-related conditions. In addition, we sought medical indications that have yielded the most promising results in the limited studies to date. We conclude that promising, yet still speculative, results have been reported for the treatment of psoriasis and enhancement of skeletal muscle activity. However, further trials are required to determine the optimal method of raising NAD levels, identifying the target conditions, and comparisons to the present standard of care for these conditions. Lastly, pharmacological methods that increase NAD levels should also be directly compared to physiological means of raising NAD levels, such as exercise programs and dietary interventions that are tailored to older individuals, and which may be more effective. View Full-Text
Keywords: nicotinamide adenine dinucleotide; NAD; pharmacology nicotinamide adenine dinucleotide; NAD; pharmacology
Show Figures

Figure 1

MDPI and ACS Style

Radenkovic, D.; Reason; Verdin, E. Clinical Evidence for Targeting NAD Therapeutically. Pharmaceuticals 2020, 13, 247. https://doi.org/10.3390/ph13090247

AMA Style

Radenkovic D, Reason, Verdin E. Clinical Evidence for Targeting NAD Therapeutically. Pharmaceuticals. 2020; 13(9):247. https://doi.org/10.3390/ph13090247

Chicago/Turabian Style

Radenkovic, Dina, Reason, and Eric Verdin. 2020. "Clinical Evidence for Targeting NAD Therapeutically" Pharmaceuticals 13, no. 9: 247. https://doi.org/10.3390/ph13090247

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop